Clinical trial · Interventional
Prevention of Chemotherapy-Induced Ovarian Failure With Goserelin in Premenopausal Lymphoma Patients
NCT04536467CI-TRIAL-00075206unknownPhase 2ClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
To Prevent Chemotherapy Induced Ovarian Failure with the gonadotropin-releasing hormone Agonist Goserelin in Young female Lymphoma Cancer patients Receiving Chemotherapy
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Premature Ovarian Failure | — | UNRESOLVED | — |
Interventions
Interventions (2)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| Chemotherapy | Drug | Chemotherapy | ALIAS |
| Goserelin | Drug | Goserelin | ALIAS |
Design
Arms and outcomes
Arms (2)
- type
- OTHER
- label
- Goserelin arm
- description
- 3.6 mg subcutaneous injection in the abdominal wall every 4 weeks (28 ± 3 days) plus standard chemotherapy at start of regimen for 3 months
- interventionNames
- Drug: Goserelin
- type
- OTHER
- label
- control Arm
- description
- Standard chemotherapy
- interventionNames
- Drug: Chemotherapy
Primary outcomes (1)
- measure
- prevention premature ovarian failure
- timeFrame
- 6 month from start of chemotherapy
Eligibility
Eligibility (as posted)
- Sex
- Female
- Minimum age
- 17 Years
- Maximum age
- 40 Years
Show eligibility criteria text
Inclusion Criteria: Female lymphoma patients will be included in the study if they meet the following criteria: 1. Confirmed lymphoma cancer radiological and pathological or by clinical evaluation receiving chemotherapy treatment 2. Normal FSH-level , estradiol level (FSH levels less than 10IU/L at the time of random assignment) 3. Female Age between 17- 40 years 4. Written informed consent Exclusion criteria: The patients will be excluded from the study if they have the following criteria: 1. Known hypersensitivity reaction to the investigational compounds or incorporated substances 2. Primary ovarian dysfunction, previous history of amenorrhea \>3 months 3. Age \> 40 4. Pregnant or lactating patients, prior use of hormonal contraceptives has to be discontinued before first Goserelin injection 5. patients who are unlikely to comply with trial requirements (eg, confusion, psychological or mood disturbances ,alcoholism, Vaginitis, vaginal bleeding, cardiac arrhythmia)
References
Publications (0)
Data not yet available
No reference posted for this study.